These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22960657)

  • 1. Segregation of a missense variant in enteric smooth muscle actin γ-2 with autosomal dominant familial visceral myopathy.
    Lehtonen HJ; Sipponen T; Tojkander S; Karikoski R; Järvinen H; Laing NG; Lappalainen P; Aaltonen LA; Tuupanen S
    Gastroenterology; 2012 Dec; 143(6):1482-1491.e3. PubMed ID: 22960657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial visceral myopathy diagnosed by exome sequencing of a patient with chronic intestinal pseudo-obstruction.
    Holla OL; Bock G; Busk OL; Isfoss BL
    Endoscopy; 2014 Jun; 46(6):533-7. PubMed ID: 24777424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACTG2 variants impair actin polymerization in sporadic Megacystis Microcolon Intestinal Hypoperistalsis Syndrome.
    Halim D; Hofstra RM; Signorile L; Verdijk RM; van der Werf CS; Sribudiani Y; Brouwer RW; van IJcken WF; Dahl N; Verheij JB; Baumann C; Kerner J; van Bever Y; Galjart N; Wijnen RM; Tibboel D; Burns AJ; Muller F; Brooks AS; Alves MM
    Hum Mol Genet; 2016 Feb; 25(3):571-83. PubMed ID: 26647307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial visceral myopathies: from symptom-based syndromes to actin-related diseases.
    Rubenstein PA; Mayer EA
    Gastroenterology; 2012 Dec; 143(6):1420-3. PubMed ID: 23085350
    [No Abstract]   [Full Text] [Related]  

  • 5. Phenotypic expansion of visceral myopathy associated with ACTG2 tandem base substitution.
    Klar J; Raykova D; Gustafson E; Tóthová I; Ameur A; Wanders A; Dahl N
    Eur J Hum Genet; 2015 Dec; 23(12):1679-83. PubMed ID: 25782675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo-obstruction.
    Ravenscroft G; Pannell S; O'Grady G; Ong R; Ee HC; Faiz F; Marns L; Goel H; Kumarasinghe P; Sollis E; Sivadorai P; Wilson M; Magoffin A; Nightingale S; Freckmann ML; Kirk EP; Sachdev R; Lemberg DA; Delatycki MB; Kamm MA; Basnayake C; Lamont PJ; Amor DJ; Jones K; Schilperoort J; Davis MR; Laing NG
    Neurogastroenterol Motil; 2018 Sep; 30(9):e13371. PubMed ID: 29781137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-generation familial visceral myopathy with alpha-actin-positive inclusion bodies in intestinal smooth muscle.
    Sipponen T; Karikoski R; Nuutinen H; Markkola A; Kaitila I
    J Clin Gastroenterol; 2009; 43(5):437-43. PubMed ID: 19098683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Insights into the Genetics of Fetal Megacystis: ACTG2 Mutations, Encoding γ-2 Smooth Muscle Actin in Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (Berdon Syndrome).
    Tuzovic L; Tang S; Miller RS; Rohena L; Shahmirzadi L; Gonzalez K; Li X; LeDuc CA; Guo J; Wilson A; Mills A; Glassberg K; Rotterdam H; Sepulveda AR; Zeng W; Chung WK; Anyane-Yeboa K
    Fetal Diagn Ther; 2015; 38(4):296-306. PubMed ID: 25998219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterozygous de novo and inherited mutations in the smooth muscle actin (ACTG2) gene underlie megacystis-microcolon-intestinal hypoperistalsis syndrome.
    Wangler MF; Gonzaga-Jauregui C; Gambin T; Penney S; Moss T; Chopra A; Probst FJ; Xia F; Yang Y; Werlin S; Eglite I; Kornejeva L; Bacino CA; Baldridge D; Neul J; Lehman EL; Larson A; Beuten J; Muzny DM; Jhangiani S; ; Gibbs RA; Lupski JR; Beaudet A
    PLoS Genet; 2014 Mar; 10(3):e1004258. PubMed ID: 24676022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent ACTG2 gene variation in African degenerative visceral leiomyopathy.
    Maluleke T; Mangray H; Arnold M; Moore HA; Moore SW
    Pediatr Surg Int; 2019 Apr; 35(4):439-442. PubMed ID: 30430282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms linking missense ACTG2 mutations to visceral myopathy.
    Ceron RH; Báez-Cruz FA; Palmer NJ; Carman PJ; Boczkowska M; Heuckeroth RO; Ostap EM; Dominguez R
    Sci Adv; 2024 May; 10(22):eadn6615. PubMed ID: 38820162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variants of the ACTG2 gene correlate with degree of severity and presence of megacystis in chronic intestinal pseudo-obstruction.
    Matera I; Rusmini M; Guo Y; Lerone M; Li J; Zhang J; Di Duca M; Nozza P; Mosconi M; Pini Prato A; Martucciello G; Barabino A; Morandi F; De Giorgio R; Stanghellini V; Ravazzolo R; Devoto M; Hakonarson H; Ceccherini I
    Eur J Hum Genet; 2016 Aug; 24(8):1211-5. PubMed ID: 26813947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoothelin-a is essential for functional intestinal smooth muscle contractility in mice.
    Niessen P; Rensen S; van Deursen J; De Man J; De Laet A; Vanderwinden JM; Wedel T; Baker D; Doevendans P; Hofker M; Gijbels M; van Eys G
    Gastroenterology; 2005 Nov; 129(5):1592-601. PubMed ID: 16285958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal Pathology in Patients With Pathogenic
    Kapur RP; Goldstein AM; Loeff DS; Myers CT; Paschal CR
    Pediatr Dev Pathol; 2022; 25(6):581-597. PubMed ID: 35695198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo ACTG2 mutations cause congenital distended bladder, microcolon, and intestinal hypoperistalsis.
    Thorson W; Diaz-Horta O; Foster J; Spiliopoulos M; Quintero R; Farooq A; Blanton S; Tekin M
    Hum Genet; 2014 Jun; 133(6):737-42. PubMed ID: 24337657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent arginine substitutions in the ACTG2 gene are the primary driver of disease burden and severity in visceral myopathy.
    Assia Batzir N; Kishor Bhagwat P; Larson A; Coban Akdemir Z; Bagłaj M; Bofferding L; Bosanko KB; Bouassida S; Callewaert B; Cannon A; Enchautegui Colon Y; Garnica AD; Harr MH; Heck S; Hurst ACE; Jhangiani SN; Isidor B; Littlejohn RO; Liu P; Magoulas P; Mar Fan H; Marom R; McLean S; Nezarati MM; Nugent KM; Petersen MB; Rocha ML; Roeder E; Smigiel R; Tully I; Weisfeld-Adams J; Wells KO; ; Posey JE; Lupski JR; Beaudet AL; Wangler MF
    Hum Mutat; 2020 Mar; 41(3):641-654. PubMed ID: 31769566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACTG2-Associated Visceral Myopathy With Chronic Intestinal Pseudoobstruction, Intestinal Malrotation, Hypertrophic Pyloric Stenosis, Choledochal Cyst, and a Novel Missense Mutation.
    Collins RRJ; Barth B; Megison S; Pfeifer CM; Rice LM; Harris S; Timmons CF; Rakheja D
    Int J Surg Pathol; 2019 Feb; 27(1):77-83. PubMed ID: 30019982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudo-obstruction-inducing ACTG2R257C alters actin organization and function.
    Hashmi SK; Barka V; Yang C; Schneider S; Svitkina TM; Heuckeroth RO
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient's dermal fibroblasts as disease markers for visceral myopathy.
    Viti F; Pramotton FM; Martufi M; Magrassi R; Pedemonte N; Nizzari M; Zanacchi FC; De Michele B; Alampi M; Zambito M; Santamaria G; Bajetto A; Sardar S; Tomati V; Gandullia P; Giampietro C; Florio T; Beltrame F; Vassalli M; Ceccherini I
    Biomater Adv; 2023 May; 148():213355. PubMed ID: 36893487
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.